CN106668599A - Drug for treating bronchiectasis - Google Patents
Drug for treating bronchiectasis Download PDFInfo
- Publication number
- CN106668599A CN106668599A CN201611252734.4A CN201611252734A CN106668599A CN 106668599 A CN106668599 A CN 106668599A CN 201611252734 A CN201611252734 A CN 201611252734A CN 106668599 A CN106668599 A CN 106668599A
- Authority
- CN
- China
- Prior art keywords
- parts
- triptophenolide
- medicine
- bronchiectasiss
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/583—Snakes; Lizards, e.g. chameleons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a drug for treating bronchiectasis. The drug for treating bronchiectasis comprises main raw materials in parts by weight as follows: 5-11 parts of rhizoma imperatae, 23-28 parts of gecko, 6-15 parts of eupalinolide A, 5-12 parts of emetini hydrochloridium, 17-26 parts of triptophenolide, 8-12 parts of triptophenolide, 2-4 parts of dalbergin, 3-6 parts of 7,8-dihydroxy-4-phenylcoumarin and 7-8 parts of yibeinoside A. According to the drug, the raw material components are selected strictly on the basis of the know mechanism about bronchiectasis, so that the purpose of comprehensive rehabilitation is achieved, and the drug has the characteristics of taking effect quickly and being stable in action, convenient to carry and take and free of toxic or side effects after long-time taking.
Description
Technical field
The present invention relates to a kind of field of medicine preparation, specifically a kind of medicine for treating bronchiectasiss.
Background technology
Bronchiectasis are, due to bronchus and its surrounding lung tissue chronic suppurative inflammation and fibrosiss, to make bronchial wall
Muscle and Elastic tissue destruction, cause bronchus to deform and persistently expansion.Main pathogenic be bronchial infection, obstruction and
Drawing, partly there is congenital heredity factor.Being in chronic process the bronchiectasis course of disease, typical clinical manifestations are chronic cough, cough more
A large amount of purulent sputums and spit blood repeatedly.90% patient often has spitting of blood, varying degree.Some patients, spitting of blood is probably that its is starting and only
Main suit, be clinically referred to as " dry bronchiectasis ", be common in tuberculous bronchiectasiss, pathological changes are more in superior lobar branchess trachea.
If secondary infection repeatedly, there are heating, night sweat during patient, weak, loss of appetite, become thin.When the concurrent compensatory of bronchiectasis
Or during obstructive emphysema, patient can have dyspnea, an out of breath or cyanosis, late period may occur in which pulmonary heart disease and cardiorespiratory failure
Performance.
Primary disease any age all can fall ill, but common with teenager, and many childhood are with pneumonia after measles, pertussis or influenza
Medical history, or have the medical histories such as pulmonary tuberculosis, endobronchial tuberculosises, pulmonary fibrosiss.Primary disease Later development has multiple complications, may lead
Cause lung collapse.
The bronchiectasiss cause of disease includes infection, heredity, cilium exception, immunodeficiency, foreign-body aspiration etc., and pathogeny is
The infection and bronchial obstruction infection of Bronchi-pulmonary tissue cause hyperemia, the edema of tube chamber mucosa, make the narrow and small secretions of tube chamber easy
Obstruction tube chamber, causes inadequate drainage and increases infection；Bronchial obstruction inadequate drainage can induce pulmonary infection.Current Drug therapy
There are ampicillin, amoxicillin or a quinolone antibiotic, or erythromycin, Roxithromycin, clarithromycin and Azithromycin etc. are anti-
Scorching medicine, but its therapeutic effect is undesirable and side effect is larger.But at present Chinese medicine there is also that treatment course is longer, DeGrain
The problems such as.
The content of the invention
It is an object of the invention to provide a kind of medicine for treating bronchiectasiss, to solve above-mentioned background technology in carry
The problem for going out.
For achieving the above object, the present invention provides following technical scheme：
A kind of medicine for treating bronchiectasiss, be according to the primary raw material of weight portion：Rhizoma Imperatae 5-11 parts, Gecko
23-28 parts, Eupalinolide A 6-15 parts, emetine hydrochloride 5-12 parts, triptophenolide 17-26 parts, triptophenolide 8-12 parts, Huang
Wingceltis element 2-4 parts, 7,8- dihydroxy -4- phenyl coumarin 3-6 parts, -3 β of pungent shellfish A prime-D-Glucose glycosides 7-8 parts.
As further scheme of the invention：The medicine of the treatment bronchiectasiss, according to the main original of weight portion
Expect be：Rhizoma Imperatae 6-9 parts, Gecko 25-26 parts, Eupalinolide A 6-15 parts, emetine hydrochloride 6-10 parts, triptophenolide 19-
22 parts, triptophenolide 9-11 parts, dalbergin 2-4 parts, 7,8- dihydroxy -4- phenyl coumarin 3-6 parts, the β-D- Portugals of pungent shellfish A prime -3
Polyglycoside 7-8 parts.
As further scheme of the invention：The medicine of the treatment bronchiectasiss, according to the main original of weight portion
Expect be：8 parts of Rhizoma Imperatae, 26 parts of Gecko, 12 parts of Eupalinolide A, 8 parts of emetine hydrochloride, 21 parts of triptophenolide, triptophenolide
10 parts, 3 parts of dalbergin, 5 parts of 7,8- dihydroxy -4- phenyl coumarins, -3 β of pungent shellfish A prime -8 parts of D-Glucose glycosides.
A kind of preparation method of the medicine for treating bronchiectasiss, concretely comprises the following steps：
First, in pharmaceutical grade clean area, Rhizoma Imperatae, Gecko, Eupalinolide A, hydrochloric acid are weighed by above-mentioned metering ratio and is told
Root alkali, triptophenolide, triptophenolide, dalbergin, 7,8- dihydroxy -4- phenyl coumarins, -3 β of pungent shellfish A prime-D-Glucose glycosides,
Sieve, machinery adds ultra-pure water after mixing, in placing pharmacy mixer, mix 4-8min, control RSD≤5%, tabletting after mixing
And cold drying, at 4-8 DEG C, packaging obtains final product the medicine for the treatment of bronchiectasiss to temperature control.
As further scheme of the invention：Mix 6min in concrete steps.
Compared with prior art, the invention has the beneficial effects as follows：
Medicine of the present invention is strictly selected material composition according to the understanding mechanism of bronchiectasiss, complete so as to reach
The purpose of face rehabilitation, with rapid-action, effect it is stable, carry taking convenience, long-term taking and have no toxic side effect the characteristics of.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than the embodiment of whole.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
A kind of medicine for treating bronchiectasiss, be according to the primary raw material of weight portion：5 parts of Rhizoma Imperatae, 23 parts of Gecko,
6 parts of Eupalinolide A, 5 parts of emetine hydrochloride, 17 parts of triptophenolide, 8 parts of triptophenolide, 2 parts of dalbergin, 7,8- dihydroxy-
3 parts of 4- phenyl coumarins, -3 β of pungent shellfish A prime -7 parts of D-Glucose glycosides.
A kind of preparation method of the medicine for treating bronchiectasiss, concretely comprises the following steps：
First, in pharmaceutical grade clean area, Rhizoma Imperatae, Gecko, Eupalinolide A, hydrochloric acid are weighed by above-mentioned metering ratio and is told
Root alkali, triptophenolide, triptophenolide, dalbergin, 7,8- dihydroxy -4- phenyl coumarins, -3 β of pungent shellfish A prime-D-Glucose glycosides,
Sieve, machinery adds ultra-pure water after mixing, in placing pharmacy mixer, mix 4min, control RSD≤5%, tabletting is simultaneously after mixing
Cold drying, at 4 DEG C, packaging obtains final product the medicine for the treatment of bronchiectasiss to temperature control.
Embodiment 2
A kind of medicine for treating bronchiectasiss, be according to the primary raw material of weight portion：6 parts of Rhizoma Imperatae, 25 parts of Gecko,
6 parts of Eupalinolide A, 6 parts of emetine hydrochloride, 19 parts of triptophenolide, 9 parts of triptophenolide, 2 parts of dalbergin, 7,8- dihydroxy-
3 parts of 4- phenyl coumarins, -3 β of pungent shellfish A prime -7 parts of D-Glucose glycosides.
A kind of preparation method of the medicine for treating bronchiectasiss, concretely comprises the following steps：
First, in pharmaceutical grade clean area, Rhizoma Imperatae, Gecko, Eupalinolide A, hydrochloric acid are weighed by above-mentioned metering ratio and is told
Root alkali, triptophenolide, triptophenolide, dalbergin, 7,8- dihydroxy -4- phenyl coumarins, -3 β of pungent shellfish A prime-D-Glucose glycosides,
Sieve, machinery adds ultra-pure water after mixing, in placing pharmacy mixer, mix 4min, control RSD≤5%, tabletting is simultaneously after mixing
Cold drying, at 4 DEG C, packaging obtains final product the medicine for the treatment of bronchiectasiss to temperature control.
Embodiment 3
A kind of medicine for treating bronchiectasiss, be according to the primary raw material of weight portion：8 parts of Rhizoma Imperatae, 26 parts of Gecko,
12 parts of Eupalinolide A, 8 parts of emetine hydrochloride, 21 parts of triptophenolide, 10 parts of triptophenolide, 3 parts of dalbergin, 7,8- dihydroxies
5 parts of base -4- phenyl coumarins, -3 β of pungent shellfish A prime -8 parts of D-Glucose glycosides.
A kind of preparation method of the medicine for treating bronchiectasiss, concretely comprises the following steps：
First, in pharmaceutical grade clean area, Rhizoma Imperatae, Gecko, Eupalinolide A, hydrochloric acid are weighed by above-mentioned metering ratio and is told
Root alkali, triptophenolide, triptophenolide, dalbergin, 7,8- dihydroxy -4- phenyl coumarins, -3 β of pungent shellfish A prime-D-Glucose glycosides,
Sieve, machinery adds ultra-pure water after mixing, in placing pharmacy mixer, mix 6min, control RSD≤5%, tabletting is simultaneously after mixing
Cold drying, at 6 DEG C, packaging obtains final product the medicine for the treatment of bronchiectasiss to temperature control.
Embodiment 4
A kind of medicine for treating bronchiectasiss, be according to the primary raw material of weight portion：9 parts of Rhizoma Imperatae, 26 parts of Gecko,
15 parts of Eupalinolide A, 10 parts of emetine hydrochloride, 22 parts of triptophenolide, 11 parts of triptophenolide, 4 parts of dalbergin, 7,8- dihydroxies
6 parts of base -4- phenyl coumarins, -3 β of pungent shellfish A prime -8 parts of D-Glucose glycosides.
A kind of preparation method of the medicine for treating bronchiectasiss, concretely comprises the following steps：
First, in pharmaceutical grade clean area, Rhizoma Imperatae, Gecko, Eupalinolide A, hydrochloric acid are weighed by above-mentioned metering ratio and is told
Root alkali, triptophenolide, triptophenolide, dalbergin, 7,8- dihydroxy -4- phenyl coumarins, -3 β of pungent shellfish A prime-D-Glucose glycosides,
Sieve, machinery adds ultra-pure water after mixing, in placing pharmacy mixer, mix 8min, control RSD≤5%, tabletting is simultaneously after mixing
Cold drying, at 8 DEG C, packaging obtains final product the medicine for the treatment of bronchiectasiss to temperature control.
Embodiment 5
A kind of medicine for treating bronchiectasiss, be according to the primary raw material of weight portion：11 parts of Rhizoma Imperatae, Gecko 28
Part, 15 parts of Eupalinolide A, 12 parts of emetine hydrochloride, 26 parts of triptophenolide, 12 parts of triptophenolide, 4 parts of dalbergin, 7,8- bis-
Hydroxy-4-phenyl coumarin 6 part, -3 β of pungent shellfish A prime -8 parts of D-Glucose glycosides.
A kind of preparation method of the medicine for treating bronchiectasiss, concretely comprises the following steps：
First, in pharmaceutical grade clean area, Rhizoma Imperatae, Gecko, Eupalinolide A, hydrochloric acid are weighed by above-mentioned metering ratio and is told
Root alkali, triptophenolide, triptophenolide, dalbergin, 7,8- dihydroxy -4- phenyl coumarins, -3 β of pungent shellfish A prime-D-Glucose glycosides,
Sieve, machinery adds ultra-pure water after mixing, in placing pharmacy mixer, mix 8min, control RSD≤5%, tabletting is simultaneously after mixing
Cold drying, at 8 DEG C, packaging obtains final product the medicine for the treatment of bronchiectasiss to temperature control.
Pharmacology test
1st, chronic toxicity test
With medicine obtained in the embodiment of the present invention 3 as test, using gastric infusion mode, successive administration 2 times in 24h,
Per minor tick 8h, 200mg/kg doses are administered every time, daily accumulation medicine total amount reaches 400mg medicines/kg, it is clinical equivalent to people to use
100 times of amount.After administration in 7d, mice activity, feed, excretion are normal, well-grown, and hair color light, its average weight is equal
Increase with the prolongation of experimental period.Every mice of post mortem at 8d, the perusal heart, liver, spleen, lung, kidney, brain, thymus,
Stomach, intestinal etc. do not find color and paramophia, fail to measure median lethal dose(LD 50) (LD50).As a result show：Medicine of the present invention without
Chronic toxicity.
2nd, long term toxicity test
With medicine obtained in the embodiment of the present invention 3 as test, using gastric infusion mode, medicine of the present invention is divided into into low dose
Amount, middle dosage, three groups of high dose, the drug dose of each group is respectively 40,80,120mg medicines/kg/d, equivalent to clinical dosage
10,20,30 times.After gastric infusion 24 weeks, medicine of the present invention refers to the general status of animal, hematological indices, blood biochemical
Mark without significantly impact, Systematic anatomy, organ coefficient and histopathological examination also no abnormal pathological change.Drug withdrawal 2
Also substantially change is had no week.As a result show：Medicine of the present invention does not find that overt toxicity reacts and postpones in long term toxicity test
Toxic reaction.It can be seen that, medicine non-toxic reaction of the present invention, long-term prescription is safe and reliable.
3rd, clinical trial
In October, 2015, in Beijing, 165 patients screened in hospital in April, 2016, and all patients meet bronchus
Di diagnostic criteria is (according to the 7th edition《Internal medicine》The diagnostic criteria of bronchiectasiss：According to pyoptysis expectorant repeatedly, spitting of blood
There are the respiratory tract infection medical history of induction primary disease medical history and the past, and CT or HRCT shows bronchiectasic abnormal image performance,
Primary disease can be made a definite diagnosis).Wherein male 95, women 70, minimal ages 22 years old, max age 63 years old, 35.2 years old mean age.
All patients take the medicine of the preparation of the embodiment of the present invention 3, and instructions of taking is：Daily 4mg/kg, 3 days courses for the treatment of, treat altogether
Three courses for the treatment of.
Curative effect situation criterion：Cure：Clinical symptoms are wholly absent, and breast CT check is normal；It is effective：Clinical symptoms base
This disappearance, breast CT check is clearly better；Effectively：Clinical symptoms improve, and breast CT check has taken a turn for the better；It is invalid：Clinical symptoms
Improve not substantially, before breast CT check is with treatment.
Therapeutic effect：165 patients have no adverse reaction during treating, healing 121, effective 22, effective 16, nothing
Effect 6, total effective rate 96.4%.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of spirit or essential attributes without departing substantially from the present invention, the present invention can be in other specific forms realized.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit is required rather than described above is limited, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although this specification is been described by according to embodiment, not each embodiment is only wrapped
Containing an independent technical scheme, this narrating mode of description is only that for clarity those skilled in the art should
Using description as an entirety, the technical scheme in each embodiment can also Jing it is appropriately combined, form those skilled in the art
Understandable other embodiment.
Claims (5)
1. a kind of medicine for treating bronchiectasiss, it is characterised in that the primary raw material according to weight portion is：Rhizoma Imperatae 5-11
Part, Gecko 23-28 parts, Eupalinolide A 6-15 parts, emetine hydrochloride 5-12 parts, triptophenolide 17-26 parts, triptophenolide 8-
12 parts, dalbergin 2-4 parts, 7,8- dihydroxy -4- phenyl coumarin 3-6 parts, -3 β of pungent shellfish A prime-D-Glucose glycosides 7-8 parts.
2. it is according to claim 1 treatment bronchiectasiss medicine, it is characterised in that the treatment bronchiectasis
The medicine of disease, be according to the primary raw material of weight portion：Rhizoma Imperatae 6-9 parts, Gecko 25-26 parts, Eupalinolide A 6-15 parts, salt
Sour ipecine 6-10 parts, triptophenolide 19-22 parts, triptophenolide 9-11 parts, dalbergin 2-4 parts, 7,8- dihydroxy -4- phenyl are fragrant
Legumin 3-6 parts, -3 β of pungent shellfish A prime-D-Glucose glycosides 7-8 parts.
3. it is according to claim 1 and 2 treatment bronchiectasiss medicine, it is characterised in that the treatment bronchus
The medicine of di, be according to the primary raw material of weight portion：8 parts of Rhizoma Imperatae, 26 parts of Gecko, 12 parts of Eupalinolide A, hydrochloric acid
8 parts of ipecine, 21 parts of triptophenolide, 10 parts of triptophenolide, 3 parts of dalbergin, 5 parts of 7,8- dihydroxy -4- phenyl coumarins, Xin Bei
The β of A prime-3-8 parts of D-Glucose glycosides.
4. it is a kind of as described in claim 1-3 is arbitrary treatment bronchiectasiss medicine preparation method, it is characterised in that
Concretely comprise the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh Rhizoma Imperatae, Gecko, Eupalinolide A, emetine hydrochloride,
Triptophenolide, triptophenolide, dalbergin, 7,8- dihydroxy -4- phenyl coumarins, -3 β of pungent shellfish A prime-D-Glucose glycosides, sieve,
Machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mixes 4-8min, controls RSD≤5%, tabletting and low after mixing
Temperature is dried, and at 4-8 DEG C, packaging obtains final product the medicine for the treatment of bronchiectasiss to temperature control.
5. it is according to claim 4 treatment bronchiectasiss medicine preparation method, it is characterised in that concrete steps
Middle mixing 6min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611252734.4A CN106668599A (en) | 2016-12-30 | 2016-12-30 | Drug for treating bronchiectasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611252734.4A CN106668599A (en) | 2016-12-30 | 2016-12-30 | Drug for treating bronchiectasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106668599A true CN106668599A (en) | 2017-05-17 |
Family
ID=58873527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611252734.4A Pending CN106668599A (en) | 2016-12-30 | 2016-12-30 | Drug for treating bronchiectasis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106668599A (en) |
-
2016
- 2016-12-30 CN CN201611252734.4A patent/CN106668599A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111388582B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application of preparation thereof | |
| US8394423B2 (en) | Compositions comprising apocynin, ginkgo and ginger and uses thereof | |
| CN106668599A (en) | Drug for treating bronchiectasis | |
| CN104306793B (en) | A kind of Chinese medicine preparation for treating lobar pneumonia | |
| CN103417571A (en) | Composition for treating chicken mycoplasma respiratory infection and preparing method thereof | |
| CN106619686A (en) | Western medicine for treating bronchiectasis | |
| CN106491853A (en) | A kind of Chinese medicine and western medicine combination for treating bronchiectasiss and preparation method thereof | |
| CN102008513A (en) | Method for controlling high swine fever by using nose atomization microecological preparation | |
| US11744841B2 (en) | Use of trezastilbenoside in manufacture of product for treating and/or preventing disease of respiratory system | |
| CN103830481B (en) | The medicine for the treatment of infantile respiratory tract infection repeatedly | |
| CN102872324B (en) | Traditional Chinese medicine atomized mixture for treating chest surgery postoperative respiratory distress syndrom | |
| CN106511665A (en) | Pharmaceutical for treating allergic pneumonia | |
| CN114917285B (en) | Application of polysaccharide compound in medicine for preventing and treating respiratory tract virus infection | |
| CN104474407A (en) | Traditional Chinese medicine preparation for treating pertussis | |
| CN109692255A (en) | A kind of Chinese medicine composition and its preparation method and application for treating acute tracheobronchitis | |
| CN104887945B (en) | It is a kind of to be used to treat Chinese medicine composition of lamb pneumonia and its preparation method and application | |
| CN106822133A (en) | A kind of Western medicine compound for treating acute diarrhea | |
| CN106581032A (en) | Western medicine for treating hylactic pneumonia | |
| CN106727494A (en) | A kind of Western medicine for treating Eaton agent pneumonia | |
| CN106581031A (en) | Compound Western medicine for treating pertussis | |
| CN101091716A (en) | Medication for treating bronchitis | |
| CN106511440A (en) | Compound Chinese and Western medicine composition for treating chronic dysentery and preparation method thereof | |
| JP2009108044A (en) | Pharmaceutical composition comprising azelastines and antiphlogistic enzyme agent | |
| CN106619680A (en) | Western medicine for treating chronic respiratory failure | |
| CN1293881C (en) | Compound antitussive |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170517 |
|
| WD01 | Invention patent application deemed withdrawn after publication |